From: May baseline JCV status influence the MS clinical evolution during Natalizumab treatment? Evidence from a multicenter-2 years-prospective study
Endpoint
JCV-
JCV+
p-value
ARR on 24 months
0.10 ± 0.25
0.083 ± 0.24
0.82
New T2 lesions at 24 months
5.6 ± 9.1
9.5 ± 14.9
0.23
Disability progression, n (%)
3/73 (4.1)
6/68 (8.8)
0.31